Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from RenovoRx ( (RNXT) ).
On February 5, 2026, RenovoRx announced the appointment of veteran public company executive Mark Voll as Chief Financial Officer, effective February 1, 2026, bringing more than three decades of financial leadership and IPO and M&A experience from multiple high-growth, publicly traded technology companies. The hire comes as RenovoRx transitions from a purely clinical-stage organization to a commercial-stage business on the back of growing RenovoCath sales and ongoing development of its TAMP therapy platform and TIGeR-PaC Phase III trial, with Voll expected to play a key role in stockholder communications, strategic planning, and scaling operations, supported by an expanded finance team that includes former principal accounting officer Ronald B. Kocak for a transition period and newly hired Executive Director of Finance Lilly Huang.
The most recent analyst rating on (RNXT) stock is a Hold with a $0.96 price target. To see the full list of analyst forecasts on RenovoRx stock, see the RNXT Stock Forecast page.
Spark’s Take on RNXT Stock
According to Spark, TipRanks’ AI Analyst, RNXT is a Neutral.
The score is held back primarily by weak financial performance—large operating losses and substantial cash burn despite improving revenue and a low-debt balance sheet. Technicals are comparatively supportive with the stock above major moving averages and positive MACD, while valuation is constrained by negative earnings. The latest earnings call was broadly positive on commercial expansion and trial progress, but this is partially offset by the Nasdaq bid-price compliance risk.
To see Spark’s full report on RNXT stock, click here.
More about RenovoRx
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company focused on developing targeted oncology therapies and commercializing RenovoCath, its patented, FDA-cleared local drug-delivery device for use in the peripheral vascular system, including chemotherapeutic infusion and temporary vessel occlusion. The company is in the early stages of commercializing its Trans-Arterial Micro-Perfusion (TAMP) therapy platform and the RenovoCath device as a stand-alone product, having reported approximately $900,000 in RenovoCath revenues over the first nine months of 2025 following its first commercial purchase orders in December 2024, while also advancing its Phase III TIGeR-PaC trial of an intra-arterial gemcitabine combination candidate that holds Orphan Drug Designation for pancreatic and bile duct cancers.
Average Trading Volume: 298,405
Technical Sentiment Signal: Strong Sell
Current Market Cap: $35.35M
See more insights into RNXT stock on TipRanks’ Stock Analysis page.